2025-02-11T11:50:20-06:00 2024-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2023-07-01 311611837 MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION MARC 5167371550 504 RXR PLAZA UNIONDALE NY 11556 LINDA TANTAWI CEO 5167371550 2025-02-10 1 0 DEVIN L DUNCAN P01249521 2127589700 2025-02-10 2023 2025-03-06 01:10:19Z X LUSTGARTEN FOUNDATION LINDA TANTAWI 504 RXR PLAZA UNIONDALE NY 11556 188537106 0 X WWW.LUSTGARTEN.ORG X 1998 NY THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD.THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. THROUGH FY24, THE LUSTGARTEN FOUNDATION HAS INVESTED $287.2 MILLION IN PANCREATIC CANCER RESEARCH. 16 16 28 430 0 0 19131206 21134092 0 0 -926435 1266888 92804 348048 18297575 22749028 19379059 21875654 0 0 4660459 4669479 53522 53806 3070585 4588659 4363615 28681699 30962554 -10384124 -8213526 78560475 75802153 9303185 10919729 69257290 64882424 X THE LUSTGARTEN FOUNDATION IS BOLDY LEADING THE WAY THROUGH HOPE AND INNOVATION, TURNING FEAR INTO ACTION THROUGH EDUCATION AND EMPOWERMENT, AND ADVANCING THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. SEE SCHEDULE OTHE LUSTGARTEN FOUNDATION IS BOLDY LEADING THE WAY THROUGH HOPE AND INNOVATION, TURNING FEAR INTO ACTION THROUGH EDUCATION AND EMPOWERMENT, AND ADVANCING THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FOCUSES ON TRANSLATING OUR UNDERSTANDING OF THE UNDERLYING BIOLOGY OF PANCREATIC CANCER INTO CLINICAL APPLICATIONS TO CHANGE, EXTEND, AND ULTIMATELY SAVE PATIENTS' LIVES. IN FY24, THE FOUNDATION AWARDED $21.8 MILLION TO FUEL CUTTING-EDGE PANCREATIC CANCER RESEARCH, INCLUDING 10 NEW GRANTS TO RESEARCHERS AT SEVEN LEADING INSTITUTIONS. RESEARCH EFFORTS ARE CONCENTRATED ON THREE KEY PILLARS: EARLY DETECTION AND INTERCEPTION, DRUG DEVELOPMENT, AND PERSONALIZED MEDICINE. 0 0 23621306 21875654 RESEARCH PROGRAM: THE LUSTGARTEN FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. 2024 MARKED THE FOUNDATION'S 26TH YEAR OF DRIVING PIONEERING PANCREATIC CANCER RESEARCH BREAKTHROUGHS, ACCELERATING PROGRESS FASTER THAN EVER BEFORE AND PROVIDING A MORE HOPEFUL FUTURE FOR ALL PATIENTS. SEE SCHEDULE O. 1241565 PUBLIC EDUCATION AND INFORMATION PROGRAM: THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, AND TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. SEE SCHEDULE O. 757498 PROFESSIONAL EDUCATION PROGRAM: PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH FUNDED SCIENTISTS AND DIRECTORS OF THE LABS PROGRAM SITES AND COLLABORATING ORGANIZATIONS, AS WELL AS ATTENDING/PRESENTING AT SCIENTIFIC MEETINGS. SEE SCHEDULE O. 25620369 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 28 0 1 28 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 16 16 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MO NV NH NJ NM NY NC OH OK OR PA SC TN UT VA WA WV WI X X FAISAL JAWAID 5167371555 504 RXR PLAZA UNIONDALE NY 11556 ANDREW LUSTGARTEN CHAIRMAN 2.00 0.00 X X 0 0 0 CHARLES F DOLAN CHAIRMAN EMERITUS (END 3/31/24) 2.00 0.00 X X 0 0 0 ROBERT F VIZZA CHAIRMAN EMERITUS 2.00 0.00 X X 0 0 0 JENNIE FORTUNOFF SECRETARY 2.00 0.00 X X 0 0 0 PHILIP D'AMBROSIO TREASURER 2.00 0.00 X X 0 0 0 JAMES L DOLAN VICE CHAIRMAN (END 3/31/24) 2.00 0.00 X X 0 0 0 ADAM SILVER VICE CHAIRMAN 2.00 0.00 X X 0 0 0 SOMMER BAZURO PHD DIRECTOR 2.00 0.00 X 0 0 0 JOHN H COBB DIRECTOR 2.00 0.00 X 0 0 0 JESSICA LUSTGARTEN COURTEMANCHE DIRECTOR 2.00 0.00 X 0 0 0 QUENTIN F DOLAN TRUSTEE (END 3/31/24) 2.00 0.00 X 0 0 0 MARCIA LUSTGARTEN DIRECTOR 2.00 0.00 X 0 0 0 SHEILA MAHONY DIRECTOR 2.00 0.00 X 0 0 0 CHARLES R SCHUELER DIRECTOR 2.00 0.00 X 0 0 0 WILLA SHALIT DIRECTOR 2.00 0.00 X 0 0 0 SCOTT PENBERTHY DIRECTOR 2.00 0.00 X 0 0 0 SELWYN VICKERS DIRECTOR 2.00 0.00 X 0 0 0 AARON KANTOFF DIRECTOR (AS OF 6/7/2024) 2.00 0.00 X 0 0 0 RICHARD R BARAKAT MD MBA DIRECTOR (AS OF 6/7/2024) 2.00 0.00 X 0 0 0 LINDA TANTAWI CEO 40.00 0.00 X 465053 0 55921 KERRI KAPLAN PRESIDENT 40.00 0.00 X 328848 0 49145 FAISAL JAWAID CFO 40.00 0.00 X 258102 0 46899 ANDREW RAKEMAN VP RESEARCH 40.00 0.00 X 250561 0 60476 GLEN PECK SVP TECHNOLOGY & BUSINESS INTELLIGENCE 40.00 0.00 X 260177 0 61671 JACLYN P LYMAN HEAD CLINICAL RESEARCH & DEVELOPMENT 40.00 0.00 X 175556 0 22671 STEPHANIE DERGARABEDIAN NATIONAL DIRECTOR OF DEVELOPMENT 40.00 0.00 X 156431 0 47745 SUSAN M JACOBSON DIRECTOR EXTERNAL & COMMUNITY RELATIONS 40.00 0.00 X 155304 0 38515 2050032 0 383043 14 0 1 0 FUSE FUNDRAISING GROUP LLC 12355 SUNRISE VALLEY DRIVE SUITE 24 RESTON VA 20191 DIRECT MAIL 710541 EW GROUP LLC 629 FIFTH AVENUESUITE 300 PELHAM NY 10803 EVENT SUPPORT 261312 WALKER STEWART MCKEOUGH 240 CENTRAL PARK SOUTH APT 8P NEW YORK CITY NY 10019 DONOR DEVELOPMENT 220000 JC GEEVER INC 11 RIVERSIDE DRIVE 2EW NEW YORK NY 10023 DONOR DEVELOPMENT 200278 WSI PAID SEARCH LTD 91 SKYWAY AVE SUITE 104 TORONTO ONTORIO CA M9W 6R5 DIGITAL ADVERTISEMENT 154000 8 4117019 17017073 213772 21134092 1917224 1917224 348048 348048 165090346 165740682 -650336 -650336 -650336 47396 4117019 47396 0 22749028 0 0 1614936 21137848 21137848 737806 737806 1101001 378580 576558 145863 2734725 1364998 525908 843819 115556 50866 33256 31434 445961 204447 133406 108108 272236 123664 72983 75589 53806 53806 291213 291213 832242 443040 132902 256300 823139 246942 82314 493883 490606 196242 122652 171712 259711 103884 64929 90898 246896 61724 37034 148138 69635 27854 17409 24372 50924 20370 12731 17823 DIRECT MAIL DESIGN & PR 1044206 522104 156630 365472 BANK & CREDIT CARD FEES 248428 5060 243368 6615 6615 30962554 25620369 2271600 3070585 3731289 3900693 1440671 2663022 190010 237956 382946 348034 104547 34912 72170913 68965570 923045 0 78560475 75802153 889012 917651 7382067 10002078 30000 1002106 0 9303185 10919729 X 68173573 62508499 1083717 2373925 69257290 64882424 78560475 75802153 X -8213526 3912481 10000 -83821 X 0 1 X 1 0 X 13046433 15661608 20139699 19131206 21134092 89113038 13046433 15661608 20139699 19131206 21134092 89113038 468521 88644517 2417283 3252026 1704321 1599807 2265272 11238709 219523 8150 160156 47396 435225 100786972 0.87950 0.79470 X PART II, SECTION B, LINE 10: OTHER INCOME REPRESENTS GROSS INCOME FROM FUNDRAISING EVENTS. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 18631 17531 1100 364315 330503 33812 34912 X 26756741 3912481 470266 -83821 4298926 22457815 291213 291213 22749028 31131607 460266 460266 30671341 291213 291213 30962554 PART X, LINE 2: THE FOUNDATION HAS RECEIVED A FINAL DETERMINATION LETTER FROM THE INTERNAL REVENUE SERVICE STATING THAT THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3). THE FOUNDATION IS TREATED AS A PUBLIC CHARITY AS DEFINED IN SECTIONS 509(A)(1) AND 170(B)(1)(A)(VI). THE FOUNDATION FOLLOWS THE PROVISIONS OF ACCOUNTING STANDARDS CODIFICATION (ASC) SUBTOPIC 740-10, INCOME TAXES - OVERALL (ASC 740-10), RELATING TO UNCERTAINTY IN INCOME TAXES. FOR THE FOUNDATION, ASC 740-10 IS PRIMARILY APPLICABLE TO THE INCURRENCE OF UNRELATED BUSINESS INCOME TAX ATTRIBUTABLE TO CERTAIN OF ITS INVESTMENTS. ASC 740-10 ESTABLISHES A MINIMUM THRESHOLD FOR FINANCIAL STATEMENT RECOGNITION OF THE BENEFITS OF POSITIONS TAKEN, OR EXPECTED TO BE TAKEN, IN FILING TAX RETURNS. IT REQUIRES THE EVALUATION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN, IN THE COURSE OF PREPARING THE FOUNDATION'S INCOME TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS ARE "MORE LIKELY THAN NOT" OF BEING SUSTAINED BY THE APPLICABLE TAX AUTHORITY. TAX POSITIONS NOT DEEMED TO MEET THE MORE-LIKELY THAN-NOT THRESHOLD ARE RECORDED AS TAX EXPENSE. FOR THE YEARS ENDED JUNE 30, 2024 AND 2023, THE FOUNDATION HAS NOT IDENTIFIED OR PROVIDED FOR ANY SUCH POSITIONS. PART XI, LINE 2D OTHER REVENUE INCLUDED ON AUDITED FINANCIAL STATEMENTS NOT INCLUDED ON FORM 990, PART VIII: (83,821) LOSS ON LEASE TERMINATION 1 NORTH AMERICA 0 0 GRANTMAKING PANCREATIC CANCER RESEARCH 339905 EUROPE 0 0 GRANTMAKING PANCREATIC CANCER RESEARCH 402901 0 0 0 0 0 0 742806 0 742806 NORTH AMERICA PANCREATIC CANCER RESEARCH 339905 WIRE/EFT 0 EUROPE PANCREATIC CANCER RESEARCH 402901 WIRE/EFT 0 2 0 0 0 0 0 0 0 PART I, LINE 2: GRANT MONITORING PROCESS THE ORGANIZATION REQUIRES ALL GRANTEES TO PROVIDE DETAILED REPORTING ON THEIR RESEARCH. THAT REPORTING INCLUDES ACCOUNTING FOR ALL FUNDS AND SHALL BE ACCOMPANIED BY ELECTRONIC COPIES OF ALL ARTICLES, IRRESPECTIVE OF WHETHER THEY WERE PUBLISHED, PRESENTED OR OTHERWISE DISCLOSED, CONCERNING GRANT RESEARCH WRITTEN BY THE PRINCIPAL INVESTIGATOR. FINAL GRANT ACCOUNTING IS DUE FROM THE SPONSORING INSTITUTION AND THE INSTITUTIONS AGREE TO REFUND ANY PORTION OF THE GRANT FUNDS TO THE FOUNDATION THAT WAS NOT USED FOR THE SPECIFIED PURPOSES DESCRIBED HEREIN AND RETURN TO THE FOUNDATION ANY UNEXPENDED FUNDS WITHIN THIRTY (30) DAYS AFTER THE EXPIRATION OR TERMINATION OF THE GRANT TERM, OR AT THE FOUNDATION'S OPTION, THE FOUNDATION MAY, BY WRITTEN NOTICE, ALLOW THE SPONSORING INSTITUTION TO USE ANY REMAINING GRANT FUNDS IN FURTHERANCE OF GRANT RESEARCH IN PROGRESS AT THE TIME OF SUCH EXPIRATION. THE FOUNDATION SHALL HAVE THE RIGHT TO AUDIT THE USE OF GRANT FUNDS. PART I, LINE E, COLUMN (F): METHOD OF ACCOUNTING EXPENSES ARE REPORTED USING THE ACCRUAL METHOD OF ACCOUNTING, CONSISTENT WITH THE AUDITED FINANCIAL STATEMENTS. X X X X X 1 FUSE FUNDRAISING GROUP LLC 12355 SUNRISE VALLEY DR SUITE 240 RESTON VA 20191 MAIL SOLICITATION 0 3264016 659658 2604358 MM EVENT GROUP LLC 500 SEVENTH AVENUE 8TH FLOOR NEW YORK NY 10018 EVENT CONSULTING 0 257541 53806 203735 3521557 713464 2808093 AL AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MO NV NH NJ NM NY NC OH OK OR PA SC TN UT VA WA WV WI LI WALK 670023 670023 NYC WALK 292465 292465 103 3201927 3154531 47396 32400 1150 13846 4164415 4117019 47396 32400 1150 13846 47396 0 1 JOHNS HOPKINS UNIVERSITY 1650 ORLEANS STREET BALTIMORE MD 21287 520595110 501(C)(3) 8784577 0 PANCREATIC CANCER RESEARCH COLD SPRING HARBOR LABORATORY ONE BUNGTOWN ROAD COLD SPRING HARBOR NY 11724 112013303 501(C)(3) 1987065 0 PANCREATIC CANCER RESEARCH AMERICAN ASSOCIATION FOR CANCER RESEARCH 615 CHESTNUT STREET- 17TH FLOOR PHILADELPHIA PA 191064404 236251648 501(C)(3) 975000 0 PANCREATIC CANCER RESEARCH MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501(C)(3) 1915072 0 PANCREATIC CANCER RESEARCH DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 2823857 0 PANCREATIC CANCER RESEARCH THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 NORTH TORREY PINES ROAD LA JOLLA CA 92037 952160097 501(C)(3) 1000000 0 PANCREATIC CANCER RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA PO BOX 741539 LOS ANGELES CA 90074 956006144 GOV'T 25302 0 PANCREATIC CANCER RESEARCH YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501(C)(3) 351000 0 PANCREATIC CANCER RESEARCH MASSACHUSETTES GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 500000 0 PANCREATIC CANCER RESEARCH NYU GROSSMAN SCHOOL OF MEDICINE PO BOX 415026 BOSTON MA 02241 135562308 501(C)(3) 1143584 0 PANCREATIC CANCER RESEARCH THE TRUSTEE OF THE UNIVERSITY OF PENNSYLVANIA 3400 CIVIC CENTER BLVD PHILADELPHIA PA 19104 231352685 501(C)(3) 845921 0 PANCREATIC CANCER RESEARCH THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE CHAPEL HILL NC 27599 566001393 GOV'T 150000 0 PANCREATIC CANCER RESEARCH DUKE UNIVERSITY PO BOX 104132 DURHAM NC 27708 560532129 501(C)(3) 306287 0 PANCREATIC CANCER RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 311183 0 PANCREATIC CANCER RESEARCH UNIVERSITY OF VIRGINIA 1001 N EMMET STREET CHARLOTTESVILLE VA 22903 546001796 GOV'T 44000 0 PANCREATIC CANCER RESEARCH 15 0 PART I, LINE 2: THE FOUNDATION MAKES GRANTS TO 501(C)(3) PUBLIC CHARITIES AND CERTAIN STATE UNIVERSITIES CONDUCTING PANCREATIC CANCER RESEARCH. AS PART OF THE REQUIREMENT FOR RECEIVING SUCH GRANTS, THE FOUNDATION REQUIRES PERIODIC UPDATES AND REPORTING ON SCIENTIFIC PROGRESS AND FINANCIAL EXPENDITURES. X X X 0 1 0 0 0 0 0 1 0 LINDA TANTAWI CEO 351303 0 113750 0 0 0 19188 0 36733 0 520974 0 0 0 KERRI KAPLAN PRESIDENT 260993 0 67855 0 0 0 4750 0 44395 0 377993 0 0 0 GLEN PECK SVP TECHNOLOGY & BUSINESS INTELLIGEN 214777 0 45400 0 0 0 13052 0 48619 0 321848 0 0 0 ANDREW RAKEMAN VP RESEARCH 207561 0 43000 0 0 0 12511 0 47965 0 311037 0 0 0 FAISAL JAWAID CFO 205602 0 52500 0 0 0 11631 0 35268 0 305001 0 0 0 STEPHANIE DERGARABEDIAN NATIONAL DIRECTOR OF DEVELOPMENT 139583 0 16848 0 0 0 8176 0 39569 0 204176 0 0 0 JACLYN P LYMAN HEAD CLINICAL RESEARCH & DEVELOPMENT 166931 0 8625 0 0 0 6723 0 15948 0 198227 0 0 0 SUSAN M JACOBSON DIRECTOR EXTERNAL & COMMUNITY RELATI 138504 0 16800 0 0 0 8864 0 29651 0 193819 0 0 0 PART I, LINE 4B: NONQUALIFIED RETIREMENT PLAN LINDA TANTAWI, CEO, PARTICIPATES IN A SUPPLEMENTAL NONQUALIFIED RETIREMENTPLAN, AND $1,150 OF DEFERRED COMPENSATION RELATED TO THE PLAN IS REPORTED ON SCHEDULE J, PART II, COLUMN (C). PART I, LINE 7: NONFIXED PAYMENTS IN 2023, OFFICERS AND EMPLOYEES RECEIVED NONFIXED DISCRETIONARY BONUSES AS REPORTED ON SCHEDULE J, PART II, COLUMN (B)(II). X 24 213772 AVG MKT VALUE 0 0 1 0 SCHEDULE M, PART I, COLUMN (B) THE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART III, LINE 4A RESEARCH PROGRAM $23,621,306 GRANTS $21,875,654 THE LUSTGARTEN FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. 2024 MARKED THE FOUNDATION'S 26TH YEAR OF DRIVING PIONEERING PANCREATIC CANCER RESEARCH BREAKTHROUGHS, ACCELERATING PROGRESS FASTER THAN EVER BEFORE AND PROVIDING A MORE HOPEFUL FUTURE FOR ALL PATIENTS. IN 2024, THE FOUNDATION AWARDED 10 NEW GRANTS TOTALING UP TO $10.3 MILLION TO RESEARCHERS AT SEVEN LEADING INSTITUTIONS. OF THE NEW GRANTS AWARDED, 30% SUPPORT DRUG DEVELOPMENT PROJECTS; 30% SUPPORT EARLY DETECTION AND INTERCEPTION EFFORTS; AND 40% SUPPORT PERSONALIZED MEDICINE STUDIES. WITH THE ADDITION OF THESE NEW GRANTS, THE FOUNDATION NOW SUPPORTS 62 ACTIVE GRANTS ACROSS 33 INSTITUTIONS. THE CUMULATIVE TOTAL THE LUSTGARTEN FOUNDATION INVESTED IN RESEARCH THROUGH JUNE 2024 IS $287.2 MILLION. DURING FY24, MAJOR LUSTGARTEN-FUNDED INITIATIVES INCLUDED: - THE LUSTGARTEN FOUNDATION-SWIM ACROSS AMERICA-AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) EARLY DETECTION RESEARCH GRANT WAS AWARDED TO RENATO OSTUNI, PHD, UNIVERSITA VITA-SALUTE, SAN RAFFAELE, ITLAY, FOR HIS STUDY, "TARGETING THE PGE2-IL-1B AXIS FOR PDAC DIAGNOSIS AND EARLY TREATMENT." - ELLIOT FISHMAN, MD, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, AND HIS TEAM ARE COLLABORATING WITH MICROSOFT AI FOR GOOD, TO BRING AUTOMATED TOOLS TO PANCREATIC CANCER DETECTION AND MANAGEMENT OF HIGH-RISK INDIVIDUALS. MICROSOFT RESEARCH HAS DEVELOPED AN EBM (EXPLAINABLE BOOSTING MACHINE), AND THE COLLABORATION HAS ENABLED THE JOHNS HOPKINS TEAM TO DEVELOP AND EVALUATE TWO AI MODELS FOR PATIENTS WITH PANCREATIC CYSTS, USING CLINICAL FEATURES ALONE OR COMBINED WITH THEIR CUSTOM-DESIGNED SOFTWARE. DR. FISHMAN AND HIS COLLEAGUES ARE ALSO COLLABORATING WITH THE MICROSOFT TEAM TO OPTIMIZE THE EARLY DETECTION OF SMALL PANCREATIC TUMORS MEASURING 2 CM OR LESS. DR. ALAN YUILLE'S STUDY AT JOHNS HOPKINS BUILDS ON THE SUCCESS OF THE FELIX PROGRAM, FUNDED BY LUSTGARTEN SINCE 2016. THE FELIX PROGRAM USES DATA FROM THOUSANDS OF CT SCANS TO TEACH COMPUTERS TO DETECT TUMORS SMALL ENOUGH TO BE MISSED BY EVEN THE MOST EXPERIENCED RADIOLOGISTS. ENTITLED "FELIX CIVITAS," THIS PROJECT INVOLVES RESEARCHERS WORKING TO ENSURE THE AI ALGORITHMS WILL ASSIST DOCTORS AND RADIOLOGISTS IN A WAY THAT ALIGNS BEST WITH THEIR NEEDS AND PRIORITIES. - THE LUSTGARTEN ADVANCING BREAKTHROUGH SCIENCE (LABS) PROGRAM, A HALLMARK OF THE FOUNDATION'S UNIQUE RESEARCH STRATEGY, HAD AN INCREDIBLY SUCCESSFUL YEAR ADVANCING RESEARCH AT ITS SIX DEDICATED LABORATORIES. SPECIFICALLY, THE LABS SITE AT DANA-FARBER CANCER INSTITUTE, LED BY BRIAN WOLPIN, MD, MPH, IS EVALUATING NOVEL SURVEILLANCE METHODS TO IMPROVE EARLY DETECTION RATES FOR THOSE WITH AN INCREASED RISK OF PANCREATIC CANCER BASED ON FAMILY HISTORY/INHERITED RISK. BUILDING ON HER PREVIOUS WORK DEVELOPING A VACCINE FOR MUTATED KRAS, ELIZABETH JAFFEE, MD, DIRECTOR OF ONE OF THE LABS SITES AT JOHNS HOPKINS AND LUSTGARTEN'S CHIEF MEDICAL ADVISOR, IS LEADING NEW RESEARCH DEMONSTRATING THAT T CELL RECEPTORS THAT ARE SPECIFIC FOR MUTATED KRAS AND ARE PRESENT ON PATIENTS, CAN BE CLONED INTO T CELLS AND USED IN ADOPTIVE THERAPIES. THIS RESEARCH IS SO IMPORTANT BECAUSE THE KRAS GENE IS MUTATED IN THE VAST MAJORITY OF PANCREATIC CANCER PATIENTS. THE LABS PROGRAM PROVIDES LONG-TERM FUNDING TO PROMOTE THE DEVELOPMENT OF INNOVATIVE IDEAS AND SPEED THE PACE OF DISCOVERY BY INCENTIVIZING INTERDISCIPLINARY TEAM SCIENCE, INCLUDING GROUPS WITH COMPLEMENTARY EXPERTISE ACROSS THE PIPELINE FROM TARGET DISCOVERY AND VALIDATION TO PRECLINICAL DEVELOPMENT AND CLINICAL TESTING. - THE ORGANOIDS FOR PERSONALIZED THERAPY PROGRAM WAS APPROVED FOR EXPANSION INTO THE FOURTH PHASE. LED BY DAVID TUVESON, MD, PHD AT COLD SPRING HARBOR LABORATORY, ORGANOID PERSONALIZED THERAPEUTICS PHASE 4 PROJECT-OPT4" BUILDS ON PREVIOUS PHASES AND SUCCESSES, TO LEVERAGE PATIENT-DERIVED ORGANOID MODELS FOR THE STUDY OF PANCREATIC CANCER AND WILL ADVANCE THE DEVELOPMENT OF EARLY DETECTION TOOLS AND THERAPEUTIC OPTIONS.OPT4 FOCUSES ON UTILIZING PATIENT DERIVED ORGANOIDS TO INVESTIGATE PANCREATIC CANCER INITIATION, CONDUCT DRUG SCREENS FOR CLINICALLY ACTIONABLE RESULTS, AND EVALUATE KRAS INHIBITORS AND COMBINATION THERAPIES AS POTENTIAL DRUG CANDIDATES FOR PANCREATIC CANCER. ADDITIONALLY, THE PASS-01 TRIAL, A LANDMARK STUDY FUNDED BY LUSTGARTEN IN COLLABORATION WITH STAND UP TO CANCER AND PANCREATIC CANCER CANADA, COMPLETED ENROLLMENT OF 146 METASTATIC PANCREATIC CANCER PATIENTS IN 2024 AND GENERATED THE MOST COMPREHENSIVE MOLECULAR ANALYSIS OF A COHORT OF THIS SIZE IN PANCREATIC CANCER. - THE LUSTGARTEN FOUNDATION-AACR CAREER DEVELOPMENT AWARDS HONORING RUTH BADER GINSBURG AND JOHN ROBERT LEWIS WERE GIVEN TO TRACY LIU, PHD, WEST VIRGINIA UNIVERSITY, FOR HER STUDY, "EXPANDING IMMUNOTHERAPY IN PANCREATIC CANCER BY TARGETING MYELOPEROXIDASE, AND CHRISTINA TOWERS, PHD, SALK INSTITUTE FOR BIOLOGICAL STUDIES, FOR HER STUDY, "TARGETING METABOLIC ADAPTATIONS TO AUTOPHAGY INHIBITION IN PDAC." THESE AWARDS FOSTER AND GROW THE NUMBER OF EARLY-CAREER WOMEN AND UNDERREPRESENTED SCIENTISTS WORKING IN PANCREATIC CANCER RESEARCH AND HONOR THE LIVES AND LEGACIES OF TWO ICONIC AMERICANS LOST TO PANCREATIC CANCER. THE AWARDS SUPPORT TRAILBLAZING INVESTIGATORS COMMITTED TO INCREASING THE UNDERSTANDING AND TREATMENT OF PANCREATIC CANCER. - THE LUSTGARTEN EQUITY, ACCESSIBILITY, AND DIVERSITY (LEAD) GRANT WAS PRESENTED TO FIYINFOLU BALOGUN, MD, PHD, MEMORIAL SLOAN KETTERING CANCER CENTER, FOR HIS STUDY, "INVESTIGATING THE MOLECULAR BASES OF PANCREATIC CANCER DISPARITIES IN UNDERSERVED MINORITY COMMUNITIES AND INCREASING CLINICAL TRIAL RECRUITMENT EMPLOYING LINGUISTIC INTERVENTION." THE LEAD GRANTS WERE CREATED TO INCREASE THE RECRUITMENT AND RETENTION OF UNDERREPRESENTED GROUPS IN PANCREATIC CANCER CLINICAL TRIALS. - THE INNOVATION AND COLLABORATION GRANT, WHICH PROVIDES SEED FUNDING FOR NOVEL RESEARCH PROJECTS WITH SIGNIFICANT POTENTIAL, WAS AWARDED TO LINDA RESAR, MD, JOHNS HOPKINS UNIVERSITY, FOR HER STUDY, "TARGETING HMGA1 TUMOR- STROMAL SIGNALING NETWORKS IN PANCREATIC CANCER." SHE IS INVESTIGATING THERAPIES BASED ON A PROTEIN CALLED HIGH MOBILITY GROUP A1 (HMGA1) INVOLVED IN REGULATING PATHWAYS THAT DRIVE TUMOR FORMATION AND PROGRESSION. - DR. ROBERT F. VIZZA LUSTGARTEN CLINICAL ACCELERATOR INITIATIVE (CAI) GRANTS WERE AWARDED TO KIM REISS BINDER, MD, HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA, FOR HER STUDY, "TESTING AND UNDERSTANDING ANTI-CTLA4 PLUS PARP INHIBITOR MAINTENANCE THERAPY IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE ACHIEVED STABLE DISEASE ON FOLFIRINOX;" ERIC CHRISTENSON, MD, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, FOR HIS STUDY, "A PILOT STUDY COMPARING NEOADJUVANT AND ADJUVANT GVAX VS A MUTATED KRAS PEPTIDE VACCINE GIVEN WITH ANTI-PD-1 AND ANTI-CD137 AGONIST FOR THE TREATMENT OF SURGICALLY RESECTABLE PANCREATIC ADENOCARCINOMA; AND ANDREW LOWY, MD, IN COLLABORATION WITH SHWETA JOSHI, PHD, BOTH FROM MOORES CANCER CENTER, UC SAN DIEGO, FOR THEIR STUDY, "SYK-TARGETED THERAPY WITH FOSTAMATINIB: A PROMISING AVENUE TO ENHANCE CHEMOTHERAPY RESPONSE IN PANCREATIC CANCER." --- THE CAI REDUCES THE TIME FROM CLINICAL TRIAL CONCEPT TO LAUNCH USING A LUSTGARTEN-DEVELOPED PROCESS BASED ON THE BEST AVAILABLE SCIENCE AND EMPLOYING INNOVATIVE BIOMARKERS. WITH THREE NEW TRIALS ADDED THIS YEAR, THERE ARE NOW 10 TRIALS SUPPORTED THROUGH THIS INNOVATIVE PROGRAM. --- TO MAXIMIZE THE VALUE OF THE CAI STUDIES, THE LUSTGARTEN FOUNDATION CONTINUED TO DEVELOP THE LUSTGARTEN UNITED CLINICAL INFORMATION DATABASE (LUCID) TO HOUSE THE CHARACTERISTICS OF PATIENTS ACROSS STUDIES AND LINK THEM TO PATIENT OUTCOMES. BY PROVIDING A CENTRALIZED PLATFORM FOR DATA SHARING AND ANALYSIS, LUCID PROMOTES COLLABORATION BETWEEN RESEARCHERS, LEADING TO FASTER RESEARCH ADVANCEMENTS. ADDITIONALLY, LUCID WILL HELP RESEARCHERS IDENTIFY NEW TREATMENT APPROACHES AND BIOMARKERS AND UNDERSTAND DISEASE HETEROGENEITY AND PATIENT SUBGROUPS, DETERMINING WAYS TO MATCH THE RIGHT PATIENTS TO THE RIGHT TREATMENTS AND IMPROVE OUTCOMES. - IN 2024, LUSTGARTEN CONTINUED OUR COLLABORATIONS WITH ORGANIZATIONS INCLUDING THE PANCREATIC CANCER COLLECTIVE, AMERICAN ASSOCIATION FOR CANCER RESEARCH, SWIM ACROSS AMERICA, CANCER RESEARCH INSTITUTE, AND BREAK THROUGH CANCER. THROUGH THESE PARTNERSHIPS, LUSTGARTEN BRINGS FOCUS AND STRATEGY TO PANCREATIC CANCER RESEARCH AND MAXIMIZES OUR COLLECTIVE FINANCIAL INVESTMENT SO WE CAN FUND THE MOST HIGH-RISK, HIGH-REWARD SCIENCE. FORM 990, PART III, LINE 4B PUBLIC EDUCATION AND INFORMATION PROGRAM $1,241,565 THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, AND TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. THE LUSTGARTEN FOUNDATION CREATED, PRINTED AND DISTRIBUTED MATERIALS TO UPDATE PATIENTS, CAREGIVERS, SURVIVORS, DONORS, VOLUNTEERS, WALK AND EVENT LEADERS AND CORPORATE SPONSORS ON RESEARCH DEVELOPMENTS, FOUNDATION MILESTONES, AND WALKS/EVENTS. MATERIALS INCLUDED: - LUSTGARTENLIVE! SERIES OF RESEARCH-FOCUSED, INTERACTIVE WEBINARS - PROGRESS & PROMISE NEWSLETTER - ANNUAL REPORT - IMPACT REPORT - RESEARCH MILESTONES UPDATE - MONTHLY E-NEWSLETTER WITH VIDEO INTRODUCTION - DIRECT MAIL AND ACQUISITION MAIL PIECES - MONTHLY PANCCHATS ON TWITTER, BRINGING EXPERTS AND PATIENTS TOGETHER TO DISCUSS TOPICS PERTINENT TO THE PANCREATIC CANCER COMMUNITY - INCREASED FOCUS ON VIDEO WE ALSO CONTINUED DISTRIBUTING OUR NAVIGATING PANCREATIC CANCER: A GUIDE FOR PATIENTS & CAREGIVERS HANDBOOK, CONTAINING INFORMATION ON MANAGING A PANCREATIC CANCER DIAGNOSIS AND TREATING THE DISEASE. THE BOOK AND MANY OF THE MATERIALS NOTED ABOVE ARE ACCESSIBLE AT WWW.LUSTGARTEN.ORG. FORM 990, PART III, LINE 4C PROFESSIONAL EDUCATION PROGRAM $757,498 PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH FUNDED SCIENTISTS AND DIRECTORS OF THE LABS PROGRAM SITES AND COLLABORATING ORGANIZATIONS, AS WELL AS ATTENDING/PRESENTING AT SCIENTIFIC MEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER (SU2C). ADDITIONALLY, THE LUSTGARTEN FOUNDATION PROVIDED SUPPORT FOR AACR'S PANCREAS MEETING, EARLY DETECTION PLANNING WORKSHOP WITH THE MARK FOUNDATION, THE INTERNATIONAL WOMEN'S DAY SYMPOSIUM AT THE SALK INSTITUTE FOR BIOLOGICAL STUDIES, AND THE PANCREAS COURSE AT COLD SPRING HARBOR LABORATORY. FORM 990, PART VI, SECTION A, LINE 2 CHARLES F. DOLAN, JAMES L. DOLAN AND QUENTIN F. DOLAN - FAMILY AND BUSINESS RELATIONSHIP. MARCIA LUSTGARTEN, ANDREW LUSTGARTEN AND JESSICA LUSTGARTEN COURTEMANCHE - FAMILY RELATIONSHIP. JAMES L. DOLAN, PHILIP D'AMBROSIO, AND QUENTIN F. DOLAN - BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS REVIEWED BY THE CHIEF EXECUTIVE OFFICER FOR ACCURACY AND REASONABLENESS PRIOR TO SUBMISSION TO THE IRS. ADDITIONALLY, A COMPLETE COPY OF THE FINAL RETURN IS PROVIDED TO ALL VOTING BOARD MEMBERS PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY. THE WRITTEN POLICY REQUIRES ANNUAL DISCLOSURES BY ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS, AND KEY PERSONS OF ANY INTEREST THAT COULD GIVE RISE TO CONFLICT. THE ORGANIZATION REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THE COMPLIANCE OF THE CONFLICT OF INTEREST POLICY. IN THE INSTANCE WHERE A DIRECTOR HAS A CONFLICT, THEY ARE ASKED BY THE BOARD CHAIR TO RECUSE THEMSELVES FROM DELIBERATIONS, DECISIONS AND THE VOTE. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER IS REVIEWED AND APPROVED ANNUALLY BY THE FINANCE COMMITTEE OF THE BOARD. TO SUPPORT THIS PROCESS, THE COMMITTEE UTILIZES A COMPENSATION SURVEY PROVIDED BY AN INDEPENDENT HUMAN RESOURCES CONSULTANT. THE MOST RECENT REVIEW OCCURRED IN MAY 2024. FORM 990, PART VI, SECTION C, LINE 19 AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE ON THE ORGANIZATION'S WEBSITE. IN ADDITION, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART XI, LINE 9: LOSS ON LEASE TERMINATION -83,821.